Trial results for the Phase 1/2 study investigating BMS-986288 alone and in combination with nivolumab in advanced solid cancers were posted on ClinicalTrials.gov on 2026-01-20. The study enrolled 219 participants and evaluated safety-related events across various treatment cohorts.

Background

Nivolumab is an established immunotherapy used in various advanced cancers. This study investigated BMS-986288, an investigational immunotherapy, both as a monotherapy and in combination with nivolumab for the treatment of advanced solid cancers.

Trial design

The study (NCT03994601) was a Phase 1/2 investigational immunotherapy study that enrolled 219 participants with advanced cancer. The trial aimed to determine the safety and tolerability of BMS-986288 alone and in combination with nivolumab. Interventions included BMS-986288, nivolumab, and regorafenib.

Key results

The trial reported safety-related events across various treatment cohorts. The number of participants experiencing safety-related events for "Safety Related Events for Cohorts 1A, 1B and 2B" were as follows:

Additionally, for Treatment 1A: Cohort 1, another count of 3 Participants was reported for safety related events.

What this means

The posted results provide initial safety data for BMS-986288 as a monotherapy and in combination with nivolumab in patients with advanced solid cancers. The reported participant counts for safety-related events across the various cohorts contribute to the understanding of the investigational agent's safety profile in this patient population. These data are crucial for further development and dose selection in subsequent clinical trials.

Source

The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03994601, titled "An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers," were posted on 2026-01-20 on clinicaltrials.gov.